Percent Change (as a percent)

Johnson & Johnson·Products & Services·36 segments

Breakdown

Segment	Q2 '24	Q3 '24	Q4 '24	Q1 '25	Q2 '25	Q3 '25	Q4 '25	Q1 '26
RYBREVANT + LAZCLUZE	—	—	—	—	—	99.7%	—	82.7%
TALVEY	—	—	—	48.4%	55%	60.8%	6%	76.7%
Tremfya	28.3%	13%	—	18.2%	31%	41.3%	9.5%	68.3%
CARVYKTI	59.8%	87.7%	8.4%	—	—	83.5%	6.3%	62.1%
STELARA	3.1%	-6.6%	-3.4%	-33.7%	-42.7%	-41.3%	-1.8%	-59.7%
SPRAVATO	60.2%	54.9%	—	41.9%	53.3%	61.5%	4.4%	46.4%
Tecvayli	42.9%	20.6%	—	13.3%	23.1%	31.3%	—	33.5%
Other	7.2%	15%	-0.2%	-7.2%	-16.9%	-13.1%	—	-27.8%
ERLEADA	29.8%	25.4%	—	11.9%	23.4%	18.4%	1.2%	23.1%
DARZALEX	18.4%	20.7%	0.5%	20.3%	23%	21.7%	1.3%	22.5%
OPSUMIT/OPSYNVI	—	—	—	-0.5%	6.4%	-0.8%	—	16.1%
INVEGA SUSTENNA / XEPLION / INVEGA TRINZA / TREVICTA	2.2%	1.9%	0.8%	-14.5%	-5.9%	-11.3%	—	15%
EDURANT/rilpivirine	11%	11.5%	—	10.7%	21.6%	16.4%	0.8%	14.1%
Other Oncology	84.2%	24.8%	-96.8%	21.7%	11.7%	9.7%	4.5%	-10.6%
OTHER INFECTIOUS DISEASES	-23.1%	-25.4%	-13%	-47.6%	-79.8%	-17.5%	—	-10.4%
PREZISTA/PREZCOBIX/REZOLSTA/SYMTUZA	-11%	0.6%	—	-3.7%	-9.4%	-11.6%	—	10%
SURGICAL	-0.5%	1.3%	2.9%	3.7%	9.9%	14.9%	0.8%	9.7%
Remicade	-14.9%	-9.1%	-1.2%	7.5%	15.9%	13.6%	—	-9.5%
CONCERTA/Methylphenidate	-21.5%	-24.8%	—	-16.3%	0.2%	-1.4%	-2.7%	-8%
TRAUMA	2.8%	2.6%	0.2%	0.9%	1.2%	4.2%	1.1%	8%
KNEES	8.4%	4%	—	-3%	-1.1%	7%	2%	7.9%
UPTRAVI	6.6%	14.2%	—	-3.6%	11.7%	5.6%	0.4%	7.1%
XARELTO	-7.9%	-5.2%	8.1%	33.3%	5.6%	7.4%	—	-7%
IMBRUVICA	-8.5%	-6.8%	-0.1%	-9.5%	-4.5%	-7.8%	—	-6.9%
HIPS	4.9%	1.7%	—	-3.1%	1%	6.4%	0.8%	6.5%
CONTACT LENSES / OTHER	-2.2%	4.2%	1.7%	1%	5.1%	5.2%	1%	5.5%
OTHER NEUROSCIENCE	-23.7%	-17.4%	-4.4%	-19.6%	-8.4%	-8.9%	—	-5.4%
GENERAL	-1.9%	0.8%	-0.2%	-0.5%	3.3%	3.9%	1.5%	4.9%
ADVANCED	-6.7%	-4.7%	—	-1.2%	2%	5%	0.1%	4.6%
SPINE & OTHER	-3.1%	-1.9%	—	-10.8%	-2.1%	0.3%	—	3.5%
SIMPONI / SIMPONI ARIA	1.6%	-18%	—	18.9%	28.6%	32.9%	—	-1.7%
CAPLYTA	—	—	—	—	0%	0%	0%	0%
ELECTROPHYSIOLOGY	3.1%	3.1%	3.1%	1.8%	1.8%	1.8%	1.8%	—
Abiomed	3.6%	3.6%	3.6%	—	—	—	—	—
other cardiovascular	—	—	—	1.1%	1.1%	1.1%	1.1%	—
SPINE,SPORTS & OTHER	-0.2%	-0.2%	-0.2%	-0.6%	-0.6%	-0.6%	-0.6%	—
Total	59.8%	87.7%	8.4%	—	—	83.5%	6.3%	62.1%

ELECTROPHYSIOLOGY, Abiomed, other cardiovascular, SPINE,SPORTS & OTHER are derived from annual filings.

Segments

CARVYKTIView metric

DARZALEXView metric

ERLEADAView metric

IMBRUVICAView metric

RYBREVANT + LAZCLUZEView metric

TALVEYView metric

TecvayliView metric

Other OncologyView metric

RemicadeView metric

SIMPONI / SIMPONI ARIAView metric

STELARAView metric

TremfyaView metric

CAPLYTAView metric

CONCERTA/MethylphenidateView metric

INVEGA SUSTENNA / XEPLION / INVEGA TRINZA / TREVICTAView metric

SPRAVATOView metric

OTHER NEUROSCIENCEView metric

OPSUMIT/OPSYNVIView metric

UPTRAVIView metric

OtherView metric

EDURANT/rilpivirineView metric

PREZISTA/PREZCOBIX/REZOLSTA/SYMTUZAView metric

OTHER INFECTIOUS DISEASESView metric

XARELTOView metric

HIPSView metric

KNEESView metric

TRAUMAView metric

SPINE & OTHERView metric

ADVANCEDView metric

GENERALView metric

CONTACT LENSES / OTHERView metric

SURGICALView metric

ELECTROPHYSIOLOGYView metric

AbiomedView metric

other cardiovascularView metric

SPINE,SPORTS & OTHERView metric

Segment	Q2 '24	Q3 '24	Q4 '24	Q1 '25	Q2 '25	Q3 '25	Q4 '25	Q1 '26
RYBREVANT + LAZCLUZE	—	—	—	—	—	99.7%	—	82.7%
TALVEY	—	—	—	48.4%	55%	60.8%	6%	76.7%
Tremfya	28.3%	13%	—	18.2%	31%	41.3%	9.5%	68.3%
CARVYKTI	59.8%	87.7%	8.4%	—	—	83.5%	6.3%	62.1%
STELARA	3.1%	-6.6%	-3.4%	-33.7%	-42.7%	-41.3%	-1.8%	-59.7%
SPRAVATO	60.2%	54.9%	—	41.9%	53.3%	61.5%	4.4%	46.4%
Tecvayli	42.9%	20.6%	—	13.3%	23.1%	31.3%	—	33.5%
Other	7.2%	15%	-0.2%	-7.2%	-16.9%	-13.1%	—	-27.8%
ERLEADA	29.8%	25.4%	—	11.9%	23.4%	18.4%	1.2%	23.1%
DARZALEX	18.4%	20.7%	0.5%	20.3%	23%	21.7%	1.3%	22.5%
OPSUMIT/OPSYNVI	—	—	—	-0.5%	6.4%	-0.8%	—	16.1%
INVEGA SUSTENNA / XEPLION / INVEGA TRINZA / TREVICTA	2.2%	1.9%	0.8%	-14.5%	-5.9%	-11.3%	—	15%
EDURANT/rilpivirine	11%	11.5%	—	10.7%	21.6%	16.4%	0.8%	14.1%
Other Oncology	84.2%	24.8%	-96.8%	21.7%	11.7%	9.7%	4.5%	-10.6%
OTHER INFECTIOUS DISEASES	-23.1%	-25.4%	-13%	-47.6%	-79.8%	-17.5%	—	-10.4%
PREZISTA/PREZCOBIX/REZOLSTA/SYMTUZA	-11%	0.6%	—	-3.7%	-9.4%	-11.6%	—	10%
SURGICAL	-0.5%	1.3%	2.9%	3.7%	9.9%	14.9%	0.8%	9.7%
Remicade	-14.9%	-9.1%	-1.2%	7.5%	15.9%	13.6%	—	-9.5%
CONCERTA/Methylphenidate	-21.5%	-24.8%	—	-16.3%	0.2%	-1.4%	-2.7%	-8%
TRAUMA	2.8%	2.6%	0.2%	0.9%	1.2%	4.2%	1.1%	8%
KNEES	8.4%	4%	—	-3%	-1.1%	7%	2%	7.9%
UPTRAVI	6.6%	14.2%	—	-3.6%	11.7%	5.6%	0.4%	7.1%
XARELTO	-7.9%	-5.2%	8.1%	33.3%	5.6%	7.4%	—	-7%
IMBRUVICA	-8.5%	-6.8%	-0.1%	-9.5%	-4.5%	-7.8%	—	-6.9%
HIPS	4.9%	1.7%	—	-3.1%	1%	6.4%	0.8%	6.5%
CONTACT LENSES / OTHER	-2.2%	4.2%	1.7%	1%	5.1%	5.2%	1%	5.5%
OTHER NEUROSCIENCE	-23.7%	-17.4%	-4.4%	-19.6%	-8.4%	-8.9%	—	-5.4%
GENERAL	-1.9%	0.8%	-0.2%	-0.5%	3.3%	3.9%	1.5%	4.9%
ADVANCED	-6.7%	-4.7%	—	-1.2%	2%	5%	0.1%	4.6%
SPINE & OTHER	-3.1%	-1.9%	—	-10.8%	-2.1%	0.3%	—	3.5%
SIMPONI / SIMPONI ARIA	1.6%	-18%	—	18.9%	28.6%	32.9%	—	-1.7%
CAPLYTA	—	—	—	—	0%	0%	0%	0%
ELECTROPHYSIOLOGY	3.1%	3.1%	3.1%	1.8%	1.8%	1.8%	1.8%	—
Abiomed	3.6%	3.6%	3.6%	—	—	—	—	—
other cardiovascular	—	—	—	1.1%	1.1%	1.1%	1.1%	—
SPINE,SPORTS & OTHER	-0.2%	-0.2%	-0.2%	-0.6%	-0.6%	-0.6%	-0.6%	—
Total	59.8%	87.7%	8.4%	—	—	83.5%	6.3%	62.1%

ELECTROPHYSIOLOGY, Abiomed, other cardiovascular, SPINE,SPORTS & OTHER are derived from annual filings.